HOOKIPA Pharma Dirección
Dirección controles de criterios 3/4
El CEO de HOOKIPA Pharma's es Joern Aldag , nombrado en Jun 2016, tiene una permanencia de 7.83 años. compensación anual total es $1.25M, compuesta por 31.2% salario y 68.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.073% de las acciones de la empresa, por valor de $55.05K. La antigüedad media del equipo directivo y de la junta directiva es de 7.4 años y 5 años, respectivamente.
Información clave
Joern Aldag
Chief Executive Officer (CEO)
US$1.3m
Compensación total
| Porcentaje del salario del CEO | 31.2% |
| Permanencia del CEO | 7.8yrs |
| Participación del CEO | 0.07% |
| Permanencia media de la dirección | 7.4yrs |
| Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
Recent updates
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Hookipa: Speculative Biotech With Key Catalysts In 2022
Mar 29Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Oct 01Checking Back In On HOOKIPA Pharma
Jun 22Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
Jun 08Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Apr 19If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns
Mar 15What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?
Jan 22
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
Dec 31Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$82m |
| Sep 30 2023 | n/a | n/a | -US$69m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$67m |
| Dec 31 2022 | US$1m | US$390k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$3m | US$572k | -US$76m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$2m | US$495k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$42m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$45m |
| Dec 31 2019 | US$6m | US$469k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$548k | US$362k | -US$16m |
| Dec 31 2017 | US$542k | US$339k | -US$13m |
Compensación vs. Mercado: La compensación total de Joern($USD1.25M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Joern ha sido consistente con los resultados de la empresa en el último año.
CEO
Joern Aldag (64 yo)
7.8yrs
Permanencia
US$1,250,408
Compensación
Mr. Joern Aldag has been Chief Executive Officer at Hookipa Biotech GmbH since June 16, 2016. He has been a Director of Hookipa Pharma Inc. since December 2017 and is its Chief Executive Officer since June...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$1.25m | 0.073% $ 64.3k | |
| CFO & Director | 7yrs | US$715.16k | 0.044% $ 38.5k | |
| Co-Founder | 13.3yrs | sin datos | sin datos | |
| Co-Founder | 13.3yrs | sin datos | sin datos | |
| Co-Founder | 13.3yrs | sin datos | sin datos | |
| Chief Operations Officer | less than a year | sin datos | sin datos | |
| Chief Scientific Officer | 2.1yrs | sin datos | sin datos | |
| Executive Director of Investor Relations | no data | sin datos | sin datos | |
| Executive Director of Communications | no data | sin datos | sin datos | |
| Chief Development Officer | no data | sin datos | sin datos | |
| Corporate Secretary | no data | sin datos | sin datos |
7.4yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HOOK es experimentado (7.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$1.25m | 0.073% $ 64.3k | |
| CFO & Director | 5.8yrs | US$715.16k | 0.044% $ 38.5k | |
| Independent Chairman of the Board | 7.3yrs | US$133.25k | 0.0092% $ 8.2k | |
| Scientific Advisory Member | 3.8yrs | US$23.76k | sin datos | |
| Director | 1.3yrs | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 5.4yrs | US$70.37k | 0.0050% $ 4.4k | |
| Independent Director | 5yrs | US$70.37k | 0.0046% $ 4.1k | |
| Independent Non-Executive Director | 2yrs | US$77.65k | sin datos |
5.0yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de HOOK se considera experimentada (5 años de antigüedad promedio).